zur Startseite


Veranstalter, Ort

Bendamustine plus rituximab in newly-diagnosed Waldenström macroglobulinaemia patients. A study on behalf of the French Innovative Leukaemia Organization (FILO).

Laribi K, Poulain S, Willems L, Merabet F, Le Calloch R, Eveillard JR, Herbaux C, Roos-Weil D, Chaoui D, Roussel X, Tricot S, Dupuis J, Dartigeas C, Bareau B, Bene MC, Baugier de Materre A, Leblond V.
read more ›

How I treat rituximab refractory patients with WM.

Gavriatopoulou M, Ntanasis-Stathopoulos I, Kastritis E, Dimopoulos MA.
read more ›



  • BNLI (R. Owen/UK)
  • Czech Myeloma Group (R. Hajek/Czech Republic)
  • FIL Italian Intergroup (A. Tedeschi/Italy)
  • FCGCLLWM Group (P. Morel, X. Leleu, V.LeBlond/France)
  • GLA/OSHO (C. Buske, M. Dreyling, M. Herold/Germany)    
  • Greek Myeloma Study Group (M. Dimopoulos, E. Kastritis/Greece)
  • HOVON (M.-J. Kersten/Netherlands)                                                            
  • Nordic Lymphoma Group (E. Kimby/Sweden)
  • Portuguese Lymphoma Study Group (M. Gomes da Silva/Portugal)
  • Spanish Study Group (R. Garcia Sanz/Spain)


In association with the "Australasian Leukaemia & Lymphoma Group" (ALLG).





Here you will find the communication platform of "European Consortium for Waldenstrom's Macroglobulinemia". Log in here with your user name and password. If you do not have access, you can get it by email via our contact form.